MX2021000900A - Forma cristalina de compuesto profarmaco de lanosterol y aplicacion de la misma. - Google Patents

Forma cristalina de compuesto profarmaco de lanosterol y aplicacion de la misma.

Info

Publication number
MX2021000900A
MX2021000900A MX2021000900A MX2021000900A MX2021000900A MX 2021000900 A MX2021000900 A MX 2021000900A MX 2021000900 A MX2021000900 A MX 2021000900A MX 2021000900 A MX2021000900 A MX 2021000900A MX 2021000900 A MX2021000900 A MX 2021000900A
Authority
MX
Mexico
Prior art keywords
application
crystal form
prodrug compound
lanosterol prodrug
lanosterol
Prior art date
Application number
MX2021000900A
Other languages
English (en)
Inventor
Xiaolin Li
Haiying He
Shuhui Chen
Jian Li
Zhi Luo
Yizhi Liu
Yandong Wang
Original Assignee
Guangzhou Ocusun Ophthalmic Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Ocusun Ophthalmic Biotechnology Co Ltd filed Critical Guangzhou Ocusun Ophthalmic Biotechnology Co Ltd
Publication of MX2021000900A publication Critical patent/MX2021000900A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una forma cristalina de un compuesto de fórmula (I) y a una aplicación de la misma en la preparación de un fármaco para el tratamiento de una enfermedad oftálmica. (ver Fórmula).
MX2021000900A 2018-07-25 2019-07-25 Forma cristalina de compuesto profarmaco de lanosterol y aplicacion de la misma. MX2021000900A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810826425 2018-07-25
PCT/CN2019/097773 WO2020020306A1 (zh) 2018-07-25 2019-07-25 一种羊毛甾醇前药化合物的晶型及其应用

Publications (1)

Publication Number Publication Date
MX2021000900A true MX2021000900A (es) 2021-06-15

Family

ID=69180373

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000900A MX2021000900A (es) 2018-07-25 2019-07-25 Forma cristalina de compuesto profarmaco de lanosterol y aplicacion de la misma.

Country Status (16)

Country Link
US (1) US11149055B2 (es)
EP (1) EP3828193A4 (es)
JP (1) JP7046266B2 (es)
KR (1) KR20210038596A (es)
CN (1) CN112543762B (es)
AU (1) AU2019308940B2 (es)
BR (1) BR112021001172A2 (es)
CA (1) CA3107361C (es)
CO (1) CO2021000932A2 (es)
MA (1) MA53397A (es)
MX (1) MX2021000900A (es)
PH (1) PH12021550182A1 (es)
RU (1) RU2766088C1 (es)
SG (1) SG11202100665WA (es)
WO (1) WO2020020306A1 (es)
ZA (1) ZA202100923B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020177714A1 (zh) * 2019-03-04 2020-09-10 中山大学中山眼科中心 一种羊毛甾醇前药化合物的组合物及其制备方法和应用
CA3228646A1 (en) * 2021-08-18 2023-02-23 Yandong Wang Application of steroid compound in preparation of drug for preventing and/or treating eye floaters
EP4389131A1 (en) * 2021-08-18 2024-06-26 Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. Pharmaceutical composition, preparation method therefor and application thereof
CN115737654A (zh) * 2021-09-03 2023-03-07 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂
WO2023143452A1 (zh) * 2022-01-28 2023-08-03 广州润尔眼科生物科技有限公司 甾体化合物在预防和/或治疗白内障中的应用
WO2023147640A1 (en) * 2022-02-07 2023-08-10 GERVÁSIO ALVES DA SILVA, Társis Preparation of novel triterpene alcohol derivatives with enhanced bioavailability for cancer, inflammation and pain treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757062A (en) 1985-11-01 1988-07-12 E. I. Du Pont De Nemours And Company Substituted benzoate ester prodrugs of estrogens
DE3540702A1 (de) 1985-11-16 1987-05-21 Bayer Ag 1h-pyrido-(2,3-b) (1,4)-thiazine
RU2283318C1 (ru) * 2005-02-24 2006-09-10 Любовь Степановна Ермолова Способ производства стеринов: ланостерола и холестерола из шерстного жира
EP3182977B1 (en) * 2014-08-22 2021-05-05 The Regents Of The University Of California Lanosterol for use in treating vision disorders
WO2016029197A1 (en) * 2014-08-22 2016-02-25 Kang Zhang Compositions and methods to treat and/or prevent vision disorders of the lens of the eye
ES2890667T3 (es) 2017-01-25 2022-01-21 Guangzhou Ocusun Ophthalmic Biotechnology Co Ltd Compuesto de profármaco de lanosterol y su uso del mismo

Also Published As

Publication number Publication date
EP3828193A1 (en) 2021-06-02
CA3107361A1 (en) 2020-01-30
ZA202100923B (en) 2021-10-27
AU2019308940B2 (en) 2024-02-08
WO2020020306A1 (zh) 2020-01-30
CO2021000932A2 (es) 2021-02-17
CN112543762A (zh) 2021-03-23
US20210246158A1 (en) 2021-08-12
US11149055B2 (en) 2021-10-19
MA53397A (fr) 2021-06-02
BR112021001172A2 (pt) 2021-04-27
CA3107361C (en) 2022-03-22
JP2021524499A (ja) 2021-09-13
CN112543762B (zh) 2022-11-08
KR20210038596A (ko) 2021-04-07
EP3828193A4 (en) 2022-06-29
JP7046266B2 (ja) 2022-04-01
SG11202100665WA (en) 2021-02-25
RU2766088C1 (ru) 2022-02-07
PH12021550182A1 (en) 2022-02-21
AU2019308940A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
PH12021550182A1 (en) Crystal form of lanosterol prodrug compound and application thereof
MX2018010192A (es) Inhibidores de glucosidasa.
ZA201701299B (en) Glycosidase inhibitors
MX2018010191A (es) Inhibidores de glucosidasa.
PH12018501920A1 (en) Bromodomain inhibitors
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
PH12017500711A1 (en) Compositions and methods for treating cns disorders
GEP20207160B (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
NZ725008A (en) Compounds for treating spinal muscular atrophy
MX2016007440A (es) Inhibidores del bromodominio.
MX2017015740A (es) Moduladores de ror gamma (ror?).
MX2019010085A (es) Inhibidores de la glicosidasa de sulfoximina.
EA201991253A1 (ru) Бензодиазолиевые соединения в качестве ингибиторов enac
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
MX2017015741A (es) Moduladores de ror gamma (ror?).
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
MX2017015739A (es) Moduladores de ror gamma (ror?).
PH12020550583A1 (en) Use of riluzole prodrugs to treat ataxias
JOP20190049A1 (ar) مثبطات دوبامين-b-هيدروكسيلاز
SA521431279B1 (ar) D1 مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
CY1122418T1 (el) Αγωγη ερυθρομελαλγιας
CY1122172T1 (el) Τροποποιητες θειαζολης των a3 υποδοχεων αδενοσινης